Table 8 FDA-approved therapeutic drugs for thyroid cancer and other solid tumors
Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
Thyrotropin alfa (Thyrogen) | Genzyme | Recombinant human thyroid-stimulating hormone | Thyroid cancer | 11/30/1998 | O |
Lenvatinib mesylate (Lenvima) | Eisai | Multitarget TKI (VEGFRs, FGFRs, PDGFRα, RET, and KIT) | Thyroid cancer | 02/13/2015 | P, O |
Vandetanib (Caprelsa) | Genzyme | Multitarget TKI (VEGFR2/3, EGFR, and RET) | Unresectable or metastatic medullary thyroid cancer | 04/06/2011 | P, O |
Cabozantinib S-malate (Cometriq) | Exelixis | Multitarget TKI (VEGFRs, MET, RET, FLT3, KIT, TIE2, and AXL) | Progressive, metastatic medullary thyroid cancer | 11/29/2012 | P, O |
Alitretinoin (Panretin) | Concordia | 9-cis-retinoic acid, a form of vitamin A | AIDS-related Kaposi’s sarcoma | 02/02/1999 | P, O |
Trabectedin (Yondelis) | Janssen | Alkylating drug | Liposarcoma or leiomyosarcoma | 10/23/2015 | P, O |
Olaratumab (Lartruvo) | Eli Lilly | PDGFRα-directed mAb | Soft tissue sarcoma | 10/19/2016 | P, O |
Pexidartinib HCl (Turalio) | Daiichi Sankyo | CSF1R, KIT, and FLT3 inhibitor | Tenosynovial giant cell tumor | 08/02/2019 | P, O |
Tazemetostat (Tazverik) | Epizyme | EZH2 inhibitor | Epithelioid sarcoma | 01/23/2020 | P, O |
Temozolomide (Temodar) | Merck | DNA alkylating agent | Glioblastoma | 08/11/1999 | P, O |
Dinutuximab (Unituxin) | United Therap | GD2‑directed mAb | High-risk neuroblastoma | 03/10/2015 | P, O |
Naxitamab (Danyelza) | Y-mAbs | GD2-directed mAb | High-risk neuroblastoma | 11/25/2020 | P, O |
Pemetrexed disodium (Alimta) | Eli Lilly | Folate analog | Malignant pleural mesothelioma | 02/04/2004 | P, O |
Larotrectinib sulfate (Vitrakvi) | Bayer | TRKs inhibitor | NTRK-positive solid tumors | 11/26/2018 | P, O |